NL8103784A - Farmaceutische preparaten; bereidingsmethode. - Google Patents
Farmaceutische preparaten; bereidingsmethode. Download PDFInfo
- Publication number
- NL8103784A NL8103784A NL8103784A NL8103784A NL8103784A NL 8103784 A NL8103784 A NL 8103784A NL 8103784 A NL8103784 A NL 8103784A NL 8103784 A NL8103784 A NL 8103784A NL 8103784 A NL8103784 A NL 8103784A
- Authority
- NL
- Netherlands
- Prior art keywords
- cisplatin
- microcrystalline
- sterile
- concentration
- microcrystalline cisplatin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 40
- 239000000825 pharmaceutical preparation Substances 0.000 title description 3
- 238000010411 cooking Methods 0.000 title 1
- 229960004316 cisplatin Drugs 0.000 claims description 190
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 189
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 80
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 66
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 61
- 239000000203 mixture Substances 0.000 claims description 58
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 40
- 229930195725 Mannitol Natural products 0.000 claims description 39
- 239000000594 mannitol Substances 0.000 claims description 39
- 235000010355 mannitol Nutrition 0.000 claims description 39
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 31
- 239000011780 sodium chloride Substances 0.000 claims description 31
- 239000008223 sterile water Substances 0.000 claims description 22
- 239000002245 particle Substances 0.000 claims description 21
- 238000001914 filtration Methods 0.000 claims description 20
- 229910052697 platinum Inorganic materials 0.000 claims description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 10
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- 238000009826 distribution Methods 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 238000001990 intravenous administration Methods 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- -1 alkyl ketones Chemical class 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 229910001504 inorganic chloride Inorganic materials 0.000 claims description 5
- 231100000252 nontoxic Toxicity 0.000 claims description 5
- 230000003000 nontoxic effect Effects 0.000 claims description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 4
- 238000013019 agitation Methods 0.000 claims description 4
- 150000003857 carboxamides Chemical class 0.000 claims description 4
- 150000003511 tertiary amides Chemical class 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 2
- 229910019029 PtCl4 Inorganic materials 0.000 claims 1
- 230000009969 flowable effect Effects 0.000 claims 1
- FBEIPJNQGITEBL-UHFFFAOYSA-J tetrachloroplatinum Chemical compound Cl[Pt](Cl)(Cl)Cl FBEIPJNQGITEBL-UHFFFAOYSA-J 0.000 claims 1
- 239000011800 void material Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 69
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 40
- 238000002360 preparation method Methods 0.000 description 36
- 239000000047 product Substances 0.000 description 31
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 29
- 238000003756 stirring Methods 0.000 description 21
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 18
- 239000013078 crystal Substances 0.000 description 17
- 150000001408 amides Chemical class 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 16
- 239000011521 glass Substances 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 238000002425 crystallisation Methods 0.000 description 10
- 230000008025 crystallization Effects 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 239000004809 Teflon Substances 0.000 description 9
- 229920006362 Teflon® Polymers 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 8
- 239000012065 filter cake Substances 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 238000004108 freeze drying Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000007792 addition Methods 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 239000013081 microcrystal Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000000123 paper Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000008227 sterile water for injection Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940063179 platinol Drugs 0.000 description 3
- 150000003058 platinum compounds Chemical group 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000007580 dry-mixing Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- SAVROPQJUYSBDD-UHFFFAOYSA-N formyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CO SAVROPQJUYSBDD-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- DBGSRZSKGVSXRK-UHFFFAOYSA-N 1-[2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]acetyl]-3,6-dihydro-2H-pyridine-4-carboxylic acid Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CCC(=CC1)C(=O)O DBGSRZSKGVSXRK-UHFFFAOYSA-N 0.000 description 1
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- PVCJKHHOXFKFRP-UHFFFAOYSA-N N-acetylethanolamine Chemical compound CC(=O)NCCO PVCJKHHOXFKFRP-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- IYWCBYFJFZCCGV-UHFFFAOYSA-N formamide;hydrate Chemical compound O.NC=O IYWCBYFJFZCCGV-UHFFFAOYSA-N 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 101150046339 fur gene Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- KERBAAIBDHEFDD-UHFFFAOYSA-N n-ethylformamide Chemical compound CCNC=O KERBAAIBDHEFDD-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- CLSUSRZJUQMOHH-UHFFFAOYSA-L platinum dichloride Chemical compound Cl[Pt]Cl CLSUSRZJUQMOHH-UHFFFAOYSA-L 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G55/00—Compounds of ruthenium, rhodium, palladium, osmium, iridium, or platinum
- C01G55/002—Compounds containing ruthenium, rhodium, palladium, osmium, iridium or platinum, with or without oxygen or hydrogen, and containing two or more other elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
- C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
- C01P2002/74—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by peak-intensities or a ratio thereof only
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/51—Particles with a specific particle size distribution
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/61—Micrometer sized, i.e. from 1-100 micrometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/80—Compositional purity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8130179 | 1979-10-02 | ||
| US06/081,301 US4302446A (en) | 1979-10-02 | 1979-10-02 | Pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8103784A true NL8103784A (nl) | 1983-03-01 |
Family
ID=22163311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8103784A NL8103784A (nl) | 1979-10-02 | 1981-08-12 | Farmaceutische preparaten; bereidingsmethode. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US4302446A (enExample) |
| JP (1) | JPS5832029A (enExample) |
| AT (1) | AT375326B (enExample) |
| AU (1) | AU551710B2 (enExample) |
| BE (1) | BE890192A (enExample) |
| CA (1) | CA1152289A (enExample) |
| CH (1) | CH647216A5 (enExample) |
| DE (1) | DE3133443A1 (enExample) |
| FR (1) | FR2511357B1 (enExample) |
| GB (1) | GB2103591B (enExample) |
| NL (1) | NL8103784A (enExample) |
| SE (2) | SE450830B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1153974B (it) * | 1982-09-23 | 1987-01-21 | Erba Farmitalia | Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento |
| DE3305248C2 (de) * | 1983-02-16 | 1987-04-09 | Degussa Ag, 6000 Frankfurt | Verfahren zur Reinigung von cis-Platin-(II)-diammin-dichlorid |
| NL8303657A (nl) * | 1983-10-24 | 1985-05-17 | Pharmachemie Bv | Voor injectie geschikte, stabiele, waterige, zoutzuur bevattende oplossing van cisplatine, alsmede werkwijze ter bereiding daarvan. |
| US4699978A (en) * | 1985-01-18 | 1987-10-13 | The Trustees Of Columbia University In The City Of New York | Site-specific chiral ruthenium (II) and cobalt (III) antitumor agents |
| US4686104A (en) * | 1985-04-30 | 1987-08-11 | Sloan-Kettering Institute For Cancer Research | Methods of treating bone disorders |
| JPS61293655A (ja) * | 1985-05-31 | 1986-12-24 | Trinity Ind Corp | 砂型鋳造品の砂落し装置 |
| CS269719B1 (en) * | 1986-12-29 | 1990-05-14 | Kiss Frantisek | Platinum cytostatic |
| JP2657393B2 (ja) * | 1988-05-18 | 1997-09-24 | 日本化薬株式会社 | 化学塞栓療法剤 |
| FI895340A7 (fi) * | 1988-11-14 | 1990-05-15 | Bristol Myers Squibb Co | Hypertoninen cisplatin-liuos |
| US4946689A (en) * | 1988-11-23 | 1990-08-07 | Bristol-Myers Company | Concentrated, stabilized cis-diamminedinitratoplatinum solutions for conversion to cisplatin |
| US8728536B2 (en) * | 1996-10-16 | 2014-05-20 | Etex Corporation | Chemotherapeutic composition using nanocrystalline calcium phosphate paste |
| WO1998029344A1 (fr) * | 1996-12-25 | 1998-07-09 | Nippon Kayaku Kabushiki Kaisha | Poudre de cisplatine fine et son procede de production |
| US6074626A (en) * | 1998-03-20 | 2000-06-13 | Molecular Radiation Management, Inc. | Radioactive cisplatin in the treatment of cancer |
| HK1049787B (en) | 1999-10-01 | 2014-07-25 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| RU2186068C2 (ru) * | 1999-12-02 | 2002-07-27 | Институт химии и химической технологии СО РАН | Способ очистки цис-дихлороамминизопропиламинплатины (ii) |
| AUPQ641100A0 (en) * | 2000-03-23 | 2000-04-15 | Australia Nuclear Science & Technology Organisation | Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents |
| ES2277301T3 (es) * | 2000-04-24 | 2007-07-01 | Teva Pharmaceutical Industries Ltd. | Solvato de hemitartrato de zolpidem. |
| EP1600159A1 (en) | 2000-04-24 | 2005-11-30 | Teva Pharmaceutical Industries Ltd | A method for synthesizing different Zolpidem hemitartrate derivatives |
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| EP1435963A4 (en) * | 2001-09-24 | 2005-10-26 | Tosk Inc | CISPLATIN FORMULATIONS WITH REDUCED TOXICITY AND USE METHOD THEREFOR |
| DE602004028585D1 (de) * | 2003-03-15 | 2010-09-23 | Brin Tech Internat Ltd | Verpackung für Arzneimittel |
| RU2343913C2 (ru) * | 2003-03-31 | 2009-01-20 | Плива-Лахема А.С. | Фармацевтическая композиция, содержащая комплекс платины в качестве активного вещества, и способ ее получения |
| ES2284068T3 (es) * | 2003-10-16 | 2007-11-01 | Teva Pharmaceutical Industries Limited | Preparacion de candesartan cilexetilo. |
| DE602005004966T2 (de) * | 2004-01-05 | 2009-03-12 | Teva Pharmaceutical Industries Ltd. | Prozesse zur herstellung von sildenafil-base und zitratsalz |
| EP1713795A2 (en) * | 2004-02-11 | 2006-10-25 | Teva Pharmaceutical Industries Ltd. | Candesartan cilexetil polymorphs |
| RU2292210C1 (ru) * | 2005-05-03 | 2007-01-27 | Институт химии и химической технологии СО РАН (ИХХТ СО РАН) | Способ получения стерилизованной микрокристаллической цис-дихлородиамминплатины (ii) |
| US20080085882A1 (en) * | 2006-08-18 | 2008-04-10 | University Of North Texas Health Science Center At Fort Worth | Compositions and Methods for Potentiation of Cancer Agents |
| US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) * | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| RU2009133447A (ru) * | 2007-02-09 | 2011-03-20 | Пониард Фармасьютикалз, Инк. (Us) | Дозированная форма пикоплатина |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| JP2010533714A (ja) * | 2007-07-16 | 2010-10-28 | ポニアード ファーマシューティカルズ， インコーポレイテッド | ピコプラチンのための経口製剤 |
| CN102006875A (zh) * | 2008-02-08 | 2011-04-06 | 帕纳德制药公司 | 吡铂和贝伐单抗治疗结直肠癌的用途 |
| EP2249825B1 (en) | 2008-03-14 | 2015-10-07 | Bionumerik Pharmaceuticals, Inc. | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions |
| AU2008352603B2 (en) | 2008-03-14 | 2012-05-31 | Bionumerik Pharmaceuticals, Inc. | Compositions and methods of use of compounds to increase cancer patient survival time |
| US20100035853A1 (en) * | 2008-08-07 | 2010-02-11 | Hyogo College Of Medicine | Method for preventing or treating cisplatin-induced nephrotoxicity |
| RU2421231C1 (ru) * | 2010-03-15 | 2011-06-20 | Учреждение Российской академии наук Институт химии и химической технологии Сибирского отделения РАН (ИХХТ СО РАН) | Способ получения стерилизованной микрокристаллической соли цис-дихлороамминэтиламинплатины (ii) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4079121A (en) * | 1974-12-13 | 1978-03-14 | Mobil Oil Corporation | Complexes of beta platinum chloride and ammonia |
| SE445172B (sv) * | 1978-05-30 | 1986-06-09 | Bristol Myers Co | Stabil, steril vattenlosning av cisplatin i enhetsdoseringsform |
| US4273755A (en) * | 1979-08-16 | 1981-06-16 | Mpd Technology Corporation | Preparation of platinum complexes |
-
1979
- 1979-10-02 US US06/081,301 patent/US4302446A/en not_active Expired - Lifetime
-
1980
- 1980-09-29 US US06/191,982 patent/US4322391A/en not_active Expired - Lifetime
-
1981
- 1981-08-03 SE SE8104661A patent/SE450830B/sv not_active IP Right Cessation
- 1981-08-04 GB GB08123759A patent/GB2103591B/en not_active Expired
- 1981-08-07 AU AU73906/81A patent/AU551710B2/en not_active Ceased
- 1981-08-12 NL NL8103784A patent/NL8103784A/nl not_active Application Discontinuation
- 1981-08-12 JP JP56125390A patent/JPS5832029A/ja active Granted
- 1981-08-14 FR FR8115760A patent/FR2511357B1/fr not_active Expired
- 1981-08-21 CA CA000384425A patent/CA1152289A/en not_active Expired
- 1981-08-24 DE DE19813133443 patent/DE3133443A1/de active Granted
- 1981-08-28 AT AT0374981A patent/AT375326B/de not_active IP Right Cessation
- 1981-09-02 BE BE0/205848A patent/BE890192A/fr not_active IP Right Cessation
- 1981-09-10 CH CH5865/81A patent/CH647216A5/de not_active IP Right Cessation
-
1983
- 1983-02-07 SE SE8300623A patent/SE455469B/sv not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2511357A1 (fr) | 1983-02-18 |
| GB2103591A (en) | 1983-02-23 |
| FR2511357B1 (fr) | 1986-09-05 |
| BE890192A (fr) | 1982-03-02 |
| CA1152289A (en) | 1983-08-23 |
| AU7390681A (en) | 1983-02-10 |
| SE450830B (sv) | 1987-08-03 |
| JPH0313174B2 (enExample) | 1991-02-21 |
| SE8300623D0 (sv) | 1983-02-07 |
| CH647216A5 (de) | 1985-01-15 |
| AT375326B (de) | 1984-07-25 |
| SE8104661L (sv) | 1983-02-04 |
| JPS5832029A (ja) | 1983-02-24 |
| DE3133443A1 (de) | 1983-03-10 |
| ATA374981A (de) | 1983-12-15 |
| US4302446A (en) | 1981-11-24 |
| AU551710B2 (en) | 1986-05-08 |
| SE8300623L (sv) | 1983-02-07 |
| US4322391A (en) | 1982-03-30 |
| SE455469B (sv) | 1988-07-18 |
| GB2103591B (en) | 1985-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL8103784A (nl) | Farmaceutische preparaten; bereidingsmethode. | |
| US4748174A (en) | Water soluble salts of an NSAID with meglumine/glucamine | |
| ES2257038T3 (es) | Metodos y composiciones para la administracion de taxanos. | |
| CA2766291C (en) | Injectable formulations containing asenapine and method of treatment using same | |
| CN110343135A (zh) | 替诺福韦艾拉酚胺(tenofovir alafenamide)半反丁烯二酸盐 | |
| DE3333024A1 (de) | Neue pharmakologische zusammensetzungen auf basis von cis-platin und verfahren zu deren herstellung | |
| EP2926805B1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| KR880002087B1 (ko) | 항균성 나프티리딘 또는 퀴놀린 화합물의 염 및 그의 제조방법 | |
| CN102600070B (zh) | 环磷腺苷葡胺组合物注射液及其制备方法 | |
| NZ189556A (en) | Stabilised aqueous solutions of cisplatin | |
| HU183379B (en) | Process for producing stabil, concentrated cisplatine solutions | |
| DE69627209T2 (de) | Lyophilisiertes thioxanthenon-antitumormedikament | |
| EP0222257A2 (en) | A phosphocreatine containing pharmaceutical composition and method for preparing the same | |
| CN103073617B (zh) | N(2)-l-丙氨酰-l-谷氨酰胺的化合物 | |
| EP0944612B1 (en) | N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate | |
| FI72302C (fi) | Foerfarande foer framstaellning av stabilt mikrokristallint cisplatin. | |
| CS269719B1 (en) | Platinum cytostatic | |
| IE51468B1 (en) | Microcrystalline cisplatin and formulations containing it | |
| Levy et al. | Deterioration of crystalline strophanthin in aqueous solution: its relation to hydrogen ion concentration and a method for its prevention | |
| DK157484B (da) | Fremgangsmaade til fremstilling af et cisplatin-praeparat | |
| CZ8095A3 (en) | Hydrochloride of ng-monomethyl-l-arginine, process of its preparation, pharmaceutical composition containing thereof and its use in medicine | |
| RU2185152C1 (ru) | Способ приготовления суспензии фармацевтической композиции на основе субстанции генно-инженерного (рекомбинантного) инсулина человека | |
| RU2054286C1 (ru) | Платиновый цитостатик и способ его получения | |
| CN104592302A (zh) | 用于治疗癌症的化合物和方法 | |
| IT8149213A1 (it) | Procedimento per la produzione di cisplatina microcristallina e prodotto ottenuto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| DNT | Communications of changes of names of applicants whose applications have been laid open to public inspection |
Free format text: BRISTOL-MYERS SQUIBB COMPANY |
|
| BV | The patent application has lapsed |